Please protect the confidentiality of your patients by not revealing or sharing login credentials.

Already registered?
Log in above.

Or call

The Pfizer Bridge Program at:

Consumer Website


Pfizer Bridge Program
Phone: 1-800-645-1280
Fax: 1-800-479-2562

Monday - Friday
9 am to 7 pm ET
Pfizer Bridge Program
PO Box 220746
Charlotte, NC 28222-0746

Forgot User Name

Enter your email address below. Click the Submit button.

Fields with an * are required


The user name will be sent to the indicated email address once it is confirmed.

Skip Navigation Links
  ©2017 Pfizer Inc. All rights reserved. The information provided in this site is intended only for health care professionals in the United States. The products
  discussed herein may have different product labeling in different countries. 

 PP-GEN-USA-0444-01 December 2017

Important Safety Information & Indications (Scroll for Important Safety Information and Indications)

Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses.

Somatropin is contraindicated in patients with active proliferative or severe nonproliferative diabetic retinopathy.

Somatropin is contraindicated in patients with active malignancy. Because growth hormone deficiency may be a sign of pituitary or other brain tumors, the presence of such tumors should be ruled out before treatment is initiated. Somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor.

Somatropin in pharmacologic doses should not be used to treat patients with acute critical illness due to complications from open heart surgery, abdominal surgery or multiple accidental traumas, or those patients with acute respiratory failure due to an increased mortality. The safety of continuing replacement somatropin treatment for approved uses in patients who develop these illnesses has not been established.

Somatropin is contraindicated in patients with Prader-Willi syndrome who are severely obese or have respiratory impairment.

GENOTROPIN is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products. Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs.

Rx only.


GENOTROPIN is indicated for the treatment of:

  • Pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (GH)
  • Pediatric patients who have growth failure due to Prader-Willi syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing
  • Pediatric patients born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years
  • Pediatric patients who have growth failure associated with Turner syndrome (TS)
  • Idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) ≤ -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means
  • Growth hormone replacement therapy in adults with growth hormone deficiency (GHD) of either childhood- or adult-onset etiology. GHD should be confirmed as appropriate